Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

about

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

Item

http://www.wikidata.org/entity/Q57168071

description

article

@en

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

@en

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

@nl

type

Item

label

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

@en

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

@nl

prefLabel

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

@en

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

@nl

P1476

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

@en

P2093

Gouji Toyokawa

http://www.w3.org/2001/XMLSchema#string

Takaki Akamine

http://www.w3.org/2001/XMLSchema#string

Takashi Seto

http://www.w3.org/2001/XMLSchema#string

Tetsuzo Tagawa

http://www.w3.org/2001/XMLSchema#string

P2860

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

P304

5093-5101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S165511

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30174447

http://www.w3.org/2001/XMLSchema#string

P932

6110295

http://www.w3.org/2001/XMLSchema#string